Advertisement

Topics

Novartis Showcases 4 Potential Blockbusters in Its Late-Stage Pipeline

19:00 EST 13 Nov 2017 | BioSpace

RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD.

Original Article: Novartis Showcases 4 Potential Blockbusters in Its Late-Stage Pipeline

NEXT ARTICLE

More From BioPortfolio on "Novartis Showcases 4 Potential Blockbusters in Its Late-Stage Pipeline"

Advertisement
Quick Search
Advertisement
Advertisement